Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance - WFXG FOX54 Augusta - Your News One Hour Earlier

Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE FN Media Group, LLC

CORAL SPRINGS, Florida, May 22, 2014 /PRNewswire/ --


Cannabis Industry making strides in developing new patents, therapy solutions and diversified products for medical patients: Cannabis Science, Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), New Colombia Resources, Inc. (OTC: NEWC), GW Pharmaceuticals plc (NASDAQ: GWPH), and Nuvilex, Inc. (OTC: NVLX).

Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders.

To support its existing CBN patent, the company has delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer's disease.  Earlier this year the company has raised funds to facilitate Cannabis Science's R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the Company's new product to address neurobehavioral disorders.

To read the full CBIS press release, please click here: http://finance.yahoo.com/news/cannabis-science-issues-cbn-patent-110000335.html 

"Cannabis Science has made solid progress so far this year. I am proud to be a part of this team and I am very positive about our future," stated Robert Kane, CFO of Cannabis Science.

Medical Marijuana Inc. (OTC: MJNA) operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company's services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. On Wednesday, MJNA closed up .82% on over 4.7 million shares traded.

New Colombia Resources, Inc. (OTCQB: NEWC), a U.S. company with coal and other resource assets in Colombia, recently announced the engagement of Doral Studios for a market study of hemp based products in the U.S. and Latin American markets.  Once the study is concluded, the Company will decide what type of product to market, either a pain or beauty product. Doral Studios Inc. d/b/a RC Television Production has been producing English and Spanish speaking infomercials and music videos for over 15 years.  They have a state of the art production studio in Doral, FL where they have produced the most successful Spanish language infomercials on the air in the U.S. and Latin America.  They handle every aspect of an infomercial including: concept, logo, animation, graphics, passive and aggressive CTA (Call to Action), and high definition production.  They work with focus groups to determine the direction of the product or idea.  Doral Studios has long standing relationships with the biggest Spanish language broadcasters in the world.  To read the full NEWC press release, please click here:  http://finance.yahoo.com/news/colombia-resources-inc-engages-infomercial-123000777.html

GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, recently announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome. "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer.

Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, recently announced that, together with Translational Drug Development (TD2) in Scottsdale, Arizona, preparations have begun for US-based preclinical and then clinical studies on the unbearable pain and the accumulation of fluid in the abdominal cavity which are two commonly occurring symptoms associated with advanced pancreatic cancer. TD2 will study the effectiveness of Nuvilex's pancreatic cancer treatment in relieving the unbearable pain and the accumulation of abdominal fluid known as "ascites." Nuvilex's pancreatic cancer treatment, which combines the Cell-in-a-Box[(R)] live-cell encapsulation technology with the well-known anticancer drug ifosfamide, will be studied with the expectation that it can improve the quality of life of pancreatic cancer patients by relieving these two chronic symptoms usually associated with the development of advanced pancreatic cancer. The preclinical studies are being planned to commence shortly and, if successful, they will be soon followed by clinical trials in both pain severity and ascites accumulation.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand seven hundred dollars for news coverage of the current press release issued by Cannabis Science, Inc. by a non-affiliated third party.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow